Viruses that cause severe respiratory infections (VRIs) lead to the hospitalisation of more than 3 million people in the US alone each year.
There are currently no broad-spectrum antivirals approved for use in patients who become hospitalised with these sRVIs including SARS-CoV-2, complicated influenza, RSV, adenovirus, parainfluenza and rhinoviruses.
people in US hospitalised annually from 2022 onwards due to severe VRIssource: IQVIA market research Q4 2022; Sources: US CDC, HCUP, IQVIA Claims Data, PubMed; data on file
in the US, representing a population at significant risk for severe RVIssource: American Medical Association
The estimated annual US healthcare costs related to severe VRIssources: Hartnet J. Influenza Other Respi Viruses. 2022;16:906–915; Pastula ST et.al.,OFID, 2017,ofw270; Zhou JA et.al., CID, 2020, 70(5): 773-779; Disease Burden of Flu | CDC; Preliminary Medicare COVID-19 Data Snapshot (Dec 2021); ICER Report: Special Assessment of Outpatient Treatments for COVID-19 Feb 2022
It Ain’t Over Till It’s Over…but It’s Never OverDr. Anthony Fauci, New England Journal of Medicine, 26 November 2022